Quick Takeaways: Why It Matters? Elanco’s $120M expansion of its Elwood, Kansas site quadruples monoclonal antibody capacity and adds upstream/downstream processing, a pilot plant and QC lab, directly supporting its new biologics franchise (Befrena&nbs...
Quick Takeaways: Why It Matters? BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level. Ins...
